|
|
 |
|
Viewing report
|
|
|
|
Therapeutic Vaccines: More Trials and Tribulations
Datamonitor, Dec 2005, Pages: 202
Therapeutic vaccines have faced numerous setbacks in recent years. The only three vaccines to reach the market have had insignificant sales, while the pipeline has seen numerous high-profile failures and no new product launches in three years. However, new off-the-shelf generalized vaccines driven by genomic advances promise to remedy the commercial drawbacks of early personalized vaccines
Scope of this title:
- In-depth coverage of over 200 marketed and pipeline therapeutic vaccines, including forecasts for sales up to 2010 and analysis of future trends
- Profiles of 16 leading therapeutic vaccines companies, their strategic position, pipelines, partnerships and financial outlook
- Discussion of the many challenges facing therapeutic vaccine developers, and how technology evolution is driving the industry forward
- Analysis of big pharmas level of interest in the sector, their partnerships and pipelines
Highlights of this title:
Polyvalent, patient-specific vaccines have major commercial disadvantages that have limited their uptake. However, rapid scientific progress means that antigen-specific, generalized vaccines could soon offer comparable efficacy, to complement their strong commercial profile. As a result generalized vaccines are starting to dominate the pipeline.
Therapeutic vaccines development is seeing an increasing trend towards the use of multiple antigens (and adjuvants), to attack cancers or HIV from multiple angles. Combinations of therapies, and novel approaches such as prime-boost regimens are expected to yield exciting results. Partnerships will therefore become much more important
Therapeutic vaccine development is currently heavily weighted towards cancer vaccines, which account for 60.6% of all pipeline projects. However, the early-stage pipeline is starting to show greater interest in other therapeutic areas, from HIV and infectious disease to nicotine addiction, CNS and cardiovascular diseases
Reasons to order your copy:
- Understand the scientific and commercial issues that are impeding therapeutic vaccines, and learn how they can become a success in the future
- Assess the entire pipeline of therapeutic vaccines with an interactive Excel model containing details of over 200 therapeutic vaccines in development
- Analyze and benchmark leading companies strategies and pipelines, as well as big pharmas interest in the sector
Customers who bought this item also bought
Therapeutic Cancer Vaccines: Evolving Strategies and Pipeline Prospects
Pipeline Insight: Therapeutic Cancer Vaccines - A Turbulent Path from Bench to Bedside
Human Vaccines - Global Strategic Business Report
Pipeline And Commercial Insight: Influenza Vaccines - Pandemic Threat Revitalizes The Sector
Therapeutic Vaccines: Strong Innovation But Far Away From Capitalization
Pipeline and Commercial Insight: Pediatric and Adolescent Vaccines
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines
Human Vaccines - Global Market Opportunities
Therapeutic Vaccines for Cancer: On the Threshold of Success
Cancer Vaccines: Measuring Market Potential
Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for Cancer
Pipeline Insight: Cancer Vaccines and Cell Therapies - Technical Know How Needs Translation Into Clinical and Commercial Rewards
|
|
|
|
